Overview

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the multiple rising dose safety/tolerability and pharmacokinetics of MK-5823 in overweight/obese participants who are healthy and overweight/obese participants with Type 2 diabetes mellitus (T2DM).
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.